#Innovent_Biologics hashtag - Bluesky

@newsen.bsky.social

1 week ago

Innovent Biologics Unveils Promising Data on IBI3055 for Autoimmune Treatment at Summit 2026 Innovent Biologics presents preclinical results of IBI3055, a tri-specific T cell engager aimed at treating autoimmune diseases, at the Immune Resetting Summit 2026.

Innovent Biologics Unveils Promising Data on IBI3055 for Autoimmune Treatment at Summit 2026 #China #Suzhou #Innovent_Biologics #IBI3055 #T_Cell_Engager

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 week ago

Altruist Biologics' Hangzhou Facility Achieves Milestone with First Commercial License Altruist Biologics has achieved a significant milestone by securing its first commercial manufacturing license for its Hangzhou facility in China.

Altruist Biologics' Hangzhou Facility Achieves Milestone with First Commercial License #China #Hangzhou #Innovent_Biologics #NMPA #Altruist_Biologics

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Ollin Biosciences Reveals Promising Results for OLN324 Against Faricimab in Eye Disease Trials Ollin Biosciences has released groundbreaking results showing OLN324 outperforming Faricimab in treating diabetic macular edema and wet AMD.

Ollin Biosciences Reveals Promising Results for OLN324 Against Faricimab in Eye Disease Trials #China #Suzhou #Innovent_Biologics #Ollin_Biosciences #IBI324

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Innovent Biologics Reports Strong 2025 Financial Results and Strategic Developments Innovent Biologics announces record 2025 results with significant revenue growth, profitability, and a focus on global expansion in biopharmaceuticals.

Innovent Biologics Reports Strong 2025 Financial Results and Strategic Developments #China #Suzhou #Innovent_Biologics #2025_results #Biopharmaceutical_Growth

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Innovent Biologics' Efdamrofusp Alfa Marks a Milestone for nAMD Treatment in China Innovent Biologics' recent study shows Efdamrofusp Alfa is the first self-developed medication achieving extended treatment intervals for nAMD in China.

Innovent Biologics' Efdamrofusp Alfa Marks a Milestone for nAMD Treatment in China #China #Suzhou #Innovent_Biologics #Efdamrofusp_Alfa #nAMD

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Innovent's Jaypirca Approved in China for CLL Treatment Expansion Innovent Biologics has secured approval for Jaypirca in China, marking a significant advancement in treating chronic lymphocytic leukemia and small lymphocytic lymphoma.

Innovent's Jaypirca Approved in China for CLL Treatment Expansion #China #Suzhou #Innovent_Biologics #Chronic_Lymphocytic_Leukemia #Jaypirca

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Innovent and Eli Lilly Forge Alliance to Develop Oncology and Immunology Drugs Innovent Biologics collaborates with Eli Lilly for innovative oncology and immunology medicines, strengthening their enduring partnership.

Innovent and Eli Lilly Forge Alliance to Develop Oncology and Immunology Drugs #China #Suzhou #Innovent_Biologics #oncology #Lilly

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent's Mazdutide Clinical Results: A Revolutionary Impact on Type 2 Diabetes Treatment in China Innovent Biologics announces two groundbreaking Phase 3 clinical trials of Mazdutide, a dual receptor agonist for type 2 diabetes, published in Nature.

Innovent's Mazdutide Clinical Results: A Revolutionary Impact on Type 2 Diabetes Treatment in China #China #Suzhou #Innovent_Biologics #Type_2_Diabetes #Mazdutide

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent Biologics Launches Phase 1 Trial for New Gout Treatment IBI3011 Innovent Biologics has successfully dosed the first participant in a Phase 1 clinical trial for IBI3011, targeting gout treatment. This monoclonal antibody aims to revolutionize care for patients suffering from gout flares.

Innovent Biologics Launches Phase 1 Trial for New Gout Treatment IBI3011 #China #Suzhou #Innovent_Biologics #Gout_Treatment #IBI3011

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent Biologics Expands Access to Seven New Treatments in China Innovent Biologics announces the inclusion of seven innovative therapies in China's National Reimbursement Drug List, enhancing patient access to essential medications.

Innovent Biologics Expands Access to Seven New Treatments in China #China #Suzhou #Innovent_Biologics #SYCUME #TYVYT

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent Biologics and Takeda Strengthen Cancer Treatments Through Partnership Innovent Biologics has finalized its strategic collaboration with Takeda to enhance the development of advanced cancer therapies, aiming for global reach and significant breakthroughs in treatment.

Innovent Biologics and Takeda Strengthen Cancer Treatments Through Partnership #China #Suzhou #Innovent_Biologics #cancer_therapies #Takeda

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent Biologics' Mazdutide Application Accepted by China's NMPA: A New Hope for Obesity Treatment Innovent Biologics' 9 mg dosed Mazdutide has been accepted for review by China's NMPA. This novel treatment promises effective weight loss solutions for the obese population in China.

Innovent Biologics' Mazdutide Application Accepted by China's NMPA: A New Hope for Obesity Treatment #China #Suzhou #Innovent_Biologics #Mazdutide #China_NMPA

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent Biologics Achieves Milestone Inclusion in Hang Seng Index Amid Global Capital Recognition Innovent Biologics, a leading biopharmaceutical company, has been included in the Hang Seng Index, marking a significant milestone for the firm in global capital markets.

Innovent Biologics Achieves Milestone Inclusion in Hang Seng Index Amid Global Capital Recognition #China #Suzhou #biopharmaceuticals #Innovent_Biologics #Hang_Seng_Index

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Innovent Unveils Groundbreaking Research at 2025 ACR Annual Meeting Innovent Biologics showcases groundbreaking study results for innovative therapies targeting various inflammatory diseases at ACR 2025.

Innovent Unveils Groundbreaking Research at 2025 ACR Annual Meeting #China #Suzhou #Innovent_Biologics #IBI3011 #IBI3034

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Innovent Biologics and Takeda Join Forces for Next-Gen Cancer Therapies Innovent Biologics has formed a strategic partnership with Takeda, aiming to propel the global development of innovative cancer therapies, including their leading investigational medicines.

Innovent Biologics and Takeda Join Forces for Next-Gen Cancer Therapies #China #Suzhou #Innovent_Biologics #Immuno-Oncology #Takeda

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Innovent's Mazdutide Gains Approval for Diabetes Treatment in China Innovent Biologics has received NMPA approval for Mazdutide, a groundbreaking diabetes treatment, offering a new solution for type 2 diabetes control in adults in China.

Innovent's Mazdutide Gains Approval for Diabetes Treatment in China #China #Suzhou #Innovent_Biologics #Type_2_Diabetes #Mazdutide

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Innovent's Partner Ollin Shares Promising Updates on Clinical Trials of IBI324 for Vision-Related Diseases Ollin Biosciences has reported significant advancements in the clinical trials of IBI324, a bispecific antibody targeting vision-threatening diseases. The findings present a potential breakthrough for patients with wAMD and DME.

Innovent's Partner Ollin Shares Promising Updates on Clinical Trials of IBI324 for Vision-Related Diseases #USA #San_Francisco #Innovent_Biologics #Ollin_Biosciences #IBI324

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Innovent to Showcase Cutting-Edge Biomedicine Research Results at EADV 2025 Congress Innovent Biologics will present significant findings on innovative biomedicine treatments during the 34th EADV Congress in Paris, highlighting progress in various disease areas.

Innovent to Showcase Cutting-Edge Biomedicine Research Results at EADV 2025 Congress #Suzhou #Innovent_Biologics #EADV_Congress #IL-23p19

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Innovent Biologics Reports Strong Growth and Business Developments for 2025 Innovent Biologics announces significant revenue growth and strategic updates for the first half of 2025, showcasing its commitment to innovation and market expansion.

Innovent Biologics Reports Strong Growth and Business Developments for 2025 #China #Suzhou #biopharmaceuticals #Innovent_Biologics #oncology

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Innovent Biologics Achieves Landmark FDA Approval for Phase 3 Study of IBI363 in Lung Cancer Treatment Innovent Biologics has received FDA IND approval for the Phase 3 trial of IBI363, a novel treatment for advanced lung cancer. This milestone supports future immunotherapy developments.

Innovent Biologics Achieves Landmark FDA Approval for Phase 3 Study of IBI363 in Lung Cancer Treatment #United_States #FDA_Approval #San_Francisco #Innovent_Biologics #IBI363

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Innovent Biologics Gains FDA Approval for New Drug IBI3032, Targeting Metabolic Disorders Innovent Biologics has received FDA approval for its investigational drug IBI3032, a novel oral GLP-1R agonist aimed at treating metabolic diseases. The clinical trials will begin soon.

Innovent Biologics Gains FDA Approval for New Drug IBI3032, Targeting Metabolic Disorders #United_States #FDA_Approval #San_Francisco #Innovent_Biologics #IBI3032

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Innovent Biologics Publishes Phase 1 Study Results on IBI343 for Advanced Gastric Cancer Innovent Biologics has released Phase 1 clinical trial findings for IBI343, targeting advanced gastric cancer. The study results published in Nature Medicine showcase promising efficacy.

Innovent Biologics Publishes Phase 1 Study Results on IBI343 for Advanced Gastric Cancer #China #Suzhou #Innovent_Biologics #gastric_cancer #IBI343

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Innovent's Phase 3 Clinical Trial of Mazdutide Begins in China, Aiming to Combat Obstructive Sleep Apnea Innovent Biologics has begun a Phase 3 clinical trial for mazdutide, targeting obesity and obstructive sleep apnea in China. This trial aims to provide valuable data on treatment options.

Innovent's Phase 3 Clinical Trial of Mazdutide Begins in China, Aiming to Combat Obstructive Sleep Apnea #China #Suzhou #Innovent_Biologics #OSA #Mazdutide

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Innovent Biologics to Showcase Groundbreaking Research at ADA's 85th Scientific Sessions in Chicago Discover the latest advancements in biomedicine as Innovent Biologics presents innovative research at the ADA's 85th Scientific Sessions in Chicago from June 20-23.

Innovent Biologics to Showcase Groundbreaking Research at ADA's 85th Scientific Sessions in Chicago #USA #Chicago #Innovent_Biologics #Mazdutide #ADA_85th

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Innovent's IBI363 Secures Second Breakthrough Therapy Designation for Lung Cancer Treatment Innovent Biologics has received a second breakthrough therapy designation for IBI363, focusing on immuno-resistant lung cancer treatments. This innovation could reshape cancer therapy.

Innovent's IBI363 Secures Second Breakthrough Therapy Designation for Lung Cancer Treatment #China #Suzhou #Cancer_Treatment #Innovent_Biologics #IBI363

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Innovent Biologics Presents Promising Data on IBI363 for Lung Cancer at 2025 ASCO Innovent Biologics reveals encouraging results from IBI363, a novel bispecific antibody targeting advanced non-small cell lung cancer at ASCO 2025.

Innovent Biologics Presents Promising Data on IBI363 for Lung Cancer at 2025 ASCO #China #Suzhou #Innovent_Biologics #Lung_Cancer #IBI363

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Innovent Biologics Shares Promising Phase 1 Results for IBI343 in Pancreatic Cancer Treatment at ASCO 2025 At ASCO 2025, Innovent Biologics presented updated Phase 1 trial data on IBI343, showing promising efficacy in patients with advanced pancreatic cancer.

Innovent Biologics Shares Promising Phase 1 Results for IBI343 in Pancreatic Cancer Treatment at ASCO 2025 #China #Suzhou #Innovent_Biologics #IBI343 #ASCO_2025

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Innovent Biologics Reveals Promising Data for IBI363 in Colorectal Cancer Treatment at 2025 ASCO Innovent Biologics presents new clinical trial data for its IBI363 treatment at ASCO 2025, showcasing significant survival benefits in advanced colorectal cancer.

Innovent Biologics Reveals Promising Data for IBI363 in Colorectal Cancer Treatment at 2025 ASCO #China #Suzhou #Innovent_Biologics #ASCO_2025 #IBI363

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago